-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560

Benzinga·07/13/2026 16:31:02
语音播报
Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $542 to $560.